48,830
edits
Line 21: | Line 21: | ||
====When to use/not to use==== | ====When to use/not to use==== | ||
The ''College of American Pathologist'' synoptic says:<ref>Srigley JR ''et al.'', "Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland", College of American Pathologists, Version: 4.0.3.0. (June 2017), Accessed on: 10 October 2018.</ref> | The ''College of American Pathologist'' synoptic (''Cancer Protocol Template'') says:<ref>Srigley JR ''et al.'', "Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland", College of American Pathologists, Version: 4.0.3.0. (June 2017), Accessed on: 10 October 2018.</ref> | ||
*Grade all prostate specimens with adenocarcinoma except those with prior treatment changes (e.g. radiation therapy or anti-androgen change). | *Grade all prostate specimens with adenocarcinoma except those with prior treatment changes (e.g. radiation therapy or anti-androgen change). | ||
edits